- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04309695
The Zenflow Spring System Safety and Performance Study (ZEST CAN)
July 15, 2021 updated by: Zenflow, Inc.
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The purpose of the Zenflow Study (ZEST CAN) is to evaluate the safety, performance and effectiveness of the Zenflow Spring System for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hyperplasia (BPH).
It is intended that the features of the Zenflow Spring will provide an effective office-based treatment and management therapy for BPH with little or no side effects.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emily Hu
- Phone Number: 5109098237
- Email: emily@zenflow.com
Study Contact Backup
- Name: Kevin MacDonald
- Phone Number: 415-609-9875
- Email: kfmacdonald@zenflow.com
Study Locations
-
-
ONT
-
Toronto, ONT, Canada, M5T 2S8
- Recruiting
- Toronto Western Hospital
-
Contact:
- Iris Chan
- Phone Number: 5033 416 603 5800
- Email: Iris.Chan2@uhn.ca
-
Principal Investigator:
- Dean Elterman, MD, MSc, FRCSC
-
-
Quebec
-
Pointe-Claire, Quebec, Canada, H9R 5K3
- Recruiting
- Groupe Sante Brunswick
-
Contact:
- Michele Tisseur, RN
- Phone Number: 514-823-5018
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
43 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Patient is able and willing to comply with all the assessments of the study
- Patient or patient's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form
- ≥ 45 years of age
- Baseline IPSS score > 13
- Prostate volume 25 - 80 cc and prostatic urethral length between 2.5-4.5 cm measured within the past 90 days
- Failed, intolerant, or patient choice to not take a medication regimen for the treatment of LUTS
Exclusion Criteria:
- Obstructive intravesical median prostatic lobe which in the opinion of the operator would not benefit from treatment
- Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or recurrent requiring 2 or more dilations as reported in the patient's history
- Requiring self-catheterization to void.
- Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer
Any of the following, taken from a single uroflowmetry reading:
- Post-void residual volume (PVR) > 250 ml
- Peak urinary flow rate of > 15 ml/second
- < 125 ml urinary volume voided at baseline (pre-bladder urinary volume of ≥150 ml required)
- Other condition or disease that might cause urinary retention
- History of other diseases causing voiding dysfunction
- Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following successful treatment of UTI and a clean urine test), or subjects who have a history of recurrent or chronic UTIs (defined as 2 or more UTIs in the past 12 months)
- Concomitant bladder stones
- Previous pelvic irradiation or radical pelvic surgery
- Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate
- Chronic prostatitis, or recurring prostatitis within the past 12 months
- Known allergy to nickel
- Life expectancy less than 24 months
- Use of concomitant medications (e.g., anticholinergics, antispasmodics or tricyclic antidepressants) affecting bladder function
- Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy not prohibited).
- Taking 5-alpha-reductase inhibitors within 3 months of pre-treatment (baseline) evaluation
Taking one of the following within 2 weeks of pre-treatment (baseline) evaluation:
- alpha-blockers,
- imipramine,
- anticholinergics, or
- cholinergic medication gonadotropin releasing hormonal analogs
- Taking androgens, unless evidence of eugonadal state for at least 6 months.
Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:
- phenylephrine, or
- pseudoephedrine
- Future fertility concerns
- Any concurrent medical condition or illness that might prevent study completion or would confound study results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group
Receives intervention with the Zenflow Spring System.
|
The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH).
The device is intended to be a permanent implant however it may be removed if necessary.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful placement of the Zenflow Spring Implant
Time Frame: Day of discharge up to 7 days following device placement
|
Number of successful deployments and procedural successes for the Zenflow System to implant the Spring device in the OR, or in an out-patient clinical setting as compared to total treatment attempts.
|
Day of discharge up to 7 days following device placement
|
Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH) using the International Prostate Symptom Score
Time Frame: 3 month
|
At 3 months, achieve at least 30% mean improvement in International Prostate Symptom Score (IPSS) compared to baseline.
The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible.
The responses to the 7 questions are tallied for a total IPSS score.
|
3 month
|
Need for urinary catheterization
Time Frame: 7 days after the procedure
|
Achieve < 12% rate of extended post-operative urinary catheterization, defined as an occurrence of a subject requiring catheterization within the first 3 days as part of a postoperative management for inability to void, for greater than 7 days.
|
7 days after the procedure
|
Incidence of procedure or device related serious adverse events
Time Frame: 30 days after the procedure
|
Achieve < 12% rate of device or procedure related SAEs through discharge and 30 days follow up.
|
30 days after the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Sexual Health Assessment: Change in sexual health measured by change in the Sexual Health Inventory for Men (SHIM) questionnaire score
Time Frame: Baseline, 3, 6, 12, 24, 36, 48, & 60 months
|
The patient selects the most appropriate response to 5 questions about his sexual health.
Each response has an assigned value between 1 and 5.
The numeric values are tallied for a total score.
|
Baseline, 3, 6, 12, 24, 36, 48, & 60 months
|
Assessment of Pain, evaluated using a Visual Analog Score (VAS) of 1 to 10
Time Frame: Baseline, interoperative (if conscious sedation used), immediately post-treatment, 2 weeks, 1 and 3 months
|
Patient describes pain on a Visual Analog Scale (VAS).
The scale is a line labeled 1 at the far left indicating minimal pain and 10 on the right, which is maximum pain.
|
Baseline, interoperative (if conscious sedation used), immediately post-treatment, 2 weeks, 1 and 3 months
|
Assessment of Adverse Events
Time Frame: Up to 5 years
|
Rate of adverse events related to the procedure or device.
|
Up to 5 years
|
Assessment of Clavien-Dindo events
Time Frame: Up to 5 years
|
Proportion of subjects with procedure or device related adverse events classified as Clavien-Dindo Grade 3 or higher or any event resulting in persistent disability evidenced through 3 months post treatment.
|
Up to 5 years
|
Assessment of PSA
Time Frame: Up to 5 years
|
Change in PSA from baseline through 12, 24, 36, 48, & 60 months post treatment.
|
Up to 5 years
|
Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)
Time Frame: Baseline, 2 weeks, 1, 6, 12, 24, 36, 48, & 60 months
|
The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible.
The responses to the 7 questions are tallied for a total score
|
Baseline, 2 weeks, 1, 6, 12, 24, 36, 48, & 60 months
|
Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)
Time Frame: Baseline, 2 weeks, 1, 3, 6, 12, 24, 36, 48, & 60 months
|
Improvement in flow of urine as measured by uroflowmetry machine.
|
Baseline, 2 weeks, 1, 3, 6, 12, 24, 36, 48, & 60 months
|
Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)
Time Frame: Up to 5 years
|
Incidence of increase in dosage or initiation of new medication to treat symptoms of BPH.
|
Up to 5 years
|
Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)
Time Frame: 24 to 60 months
|
Incidence of repeat treatment.
|
24 to 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 9, 2021
Primary Completion (Anticipated)
December 1, 2025
Study Completion (Anticipated)
January 1, 2026
Study Registration Dates
First Submitted
March 4, 2020
First Submitted That Met QC Criteria
March 13, 2020
First Posted (Actual)
March 16, 2020
Study Record Updates
Last Update Posted (Actual)
July 19, 2021
Last Update Submitted That Met QC Criteria
July 15, 2021
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-0111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
Clinical Trials on Zenflow Spring System
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
Zenflow, Inc.Active, not recruitingBenign Prostatic HyperplasiaMexico
-
Zenflow, Inc.UnknownBenign Prostatic HyperplasiaBulgaria, New Zealand
-
Zenflow, Inc.Active, not recruitingBPH (Benign Prostatic Hyperplasia) | Lower Urinary Tract Symptoms (LUTS)United States
-
Rodney A. White, M.D.CompletedAbdominal Aortic AneurysmsUnited States
-
Spaulding Rehabilitation HospitalTerminated
-
National Rehabilitation Center, Seoul, KoreaUnknown
-
University Hospital, BrestMinistry of Health, FranceUnknown
-
University of NottinghamUniversity of MichiganCompleted
-
Shirley Ryan AbilityLabRecruiting